Please wait
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Kura Oncology, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
|
|
|
|
|
|
|
|
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee |
Equity |
Common Stock, $0.0001 par value per share, Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan |
Rule 457(c) and Rule 457(h) |
5,500,000(2) |
$21.30(3) |
$117,150,000.00(3) |
0.0001476 |
$17,291.34 |
Total Offering Amounts |
|
|
|
|
$117,150,000.00 |
|
$17,291.34 |
Total Fee Offsets |
|
|
|
|
|
|
$9,353.80(4) |
Net Fee Due |
|
|
|
|
|
|
$7,937.54 |
(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock (“Common Stock”) that become issuable under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction.
(2)Represents shares of Common Stock that were added to the shares authorized for issuance under the 2014 Plan on June 5, 2024 pursuant to stockholder approval of an amendment to the 2014 Plan.
(3)Estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on June 5, 2024, as reported on the Nasdaq Global Select Market.
(4)On February 24, 2022, the Registrant filed a prospectus supplement to its registration statement on Form S-3ASR, filed on December 7, 2020 (File No. 333-251172) (the “2020 S-3ASR”), registering the issuance of up to $150,000,000 of Common Stock (the “2022 Securities”). The registration fee associated with the 2022 Securities was $13,905.00. The 2020 S-3ASR was terminated and the Registrant has not sold any 2022 Securities pursuant to the 2020 S-3ASR. The Registrant previously applied $2,724.21 and $1,826.99 in registration fees previously paid by the Registrant with respect to 2022 Securities that were registered but not issued pursuant to the 2020 S-3ASR to a registration statement on Form S-3 filed by the Registrant on February 9, 2024 (File No. 333-276995) and to a registration statement on Form S-8 filed by the Registrant on February 27, 2024 (File No. 333-277411), respectively. Accordingly, the remaining unused registration fee paid in connection with the 2020 S-3ASR and the 2022 Securities is $9,353.80. Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $117,150,000.00 of Common Stock of the Registrant being registered hereby in the amount of $17,291.34 is partially offset by $9,353.80 in registration fees previously paid by the Registrant with respect to 2022 Securities that were registered but not issued pursuant to the 2020 S-3ASR. Accordingly, $7,937.54 in registration fees are being paid at this time.
Table 2: Fee Offset Claims and Sources
|
|
|
|
|
|
|
|
|
|
|
|
|
Registrant or Filer Name |
Form or Filing Type |
File Number |
Initial Filing Date |
Filing Date |
Fee Offset Claimed |
Security Type Associated with Fee Offset Claimed |
Security Title Associated with Fee Offset Claimed |
Unsold Securities Associated with Fee Offset Claimed |
Unsold Aggregate Offering Amount Associated with Fee Offset Claimed |
Fee Paid with Fee Offset Source |
Rule 457(p) |
Fee Offset Claims |
Kura Oncology, Inc. |
S-3ASR |
333-251172 |
12/7/2020 |
|
$9,353.80(1) |
Equity |
Common Stock |
N/A |
$150,000,000(1) |
|
Fee Offset Sources |
Kura Oncology, Inc. |
424(b)(5) |
333-251172 |
|
2/24/2022 |
|
|
|
|
|
$9,353.80 (1) |
(1)See Note (4) under Table 1 above.